Z
9.13
-0.24 (-2.56%)
| Penutupan Terdahulu | 9.37 |
| Buka | 9.24 |
| Jumlah Dagangan | 527,614 |
| Purata Dagangan (3B) | 550,107 |
| Modal Pasaran | 499,224,768 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.53 |
| Harga / Jualan (P/S) | 11.10 |
| Harga / Buku (P/B) | 12.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Keuntungan | -226.64% |
| Margin Operasi (TTM) | -26.28% |
| EPS Cair (TTM) | -1.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 495.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 150.74% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.23 M |
| Pulangan Atas Aset (ROA TTM) | -27.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -204.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Zevra Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
2.4
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.38 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.62% |
| % Dimiliki oleh Institusi | 65.41% |
| Julat 52 Minggu | ||
| Median | 25.00 (173.82%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 25.00 (173.82%) | Beli | 8.14 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 May 2025 | Pengumuman | Zevra Announces Final Results of 2025 Annual Meeting of Stockholders |
| 21 May 2025 | Pengumuman | All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees |
| 13 May 2025 | Pengumuman | Zevra Reports First Quarter 2025 Financial Results and Corporate Update |
| 06 May 2025 | Pengumuman | Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call |
| 01 May 2025 | Pengumuman | Zevra Therapeutics to Participate in the Citizens Life Science Conference |
| 21 Apr 2025 | Pengumuman | Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders |
| 17 Apr 2025 | Pengumuman | Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism |
| 07 Apr 2025 | Pengumuman | Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million |
| 31 Mar 2025 | Pengumuman | Zevra Therapeutics Files Preliminary Proxy |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |